Immunostaining of p53 protein in ovarian carcinoma: Correlation with histopathological data and clinical outcome

Journal of Cancer Research and Clinical Oncology

Volumn 122, Issue 8, 1996, Pages 489-494

  Reles, Angela ^a,d   Schmider, Annette ^a   Press, Michael F ^b   Schönborn, Ines ^a   Friedmann, Wolfgang ^a   Huber Schumacher, S ^a   Strohmeyer, Torsten ^c   Lichtenegger, Werner ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c BAYER PHARMA AG   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

immunohistochemistry; ovarian carcinoma; p53; tumor suppressor gene

Indexed keywords

MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MUTATION; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030010914     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01187161     Document Type: Article

References (40)

1. Banks L, Matlashewski G, Crawford L (1986) Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 159: 529-534
2. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, Kovarik J, Midgley CA, Gannon JV, Lane DP (1991) Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 6: 1699-1703
3. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC (1994) The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 170: 246-252
4. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ (1991) Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 6: 1791-1797
5. Day TG, Gallager HS, Rutledge FN (1975) Epithelial carcinoma of the ovary: Prognostic importance of histological grade. Natl Cancer Inst Monogr 42: 15-18
6. Eccles DM, Brett L, Lessells A, Gruber L, Lane D, Steel CM, Leonard RCF (1992) Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 65: 40-44
7. El Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B (1992) Definition of a consensus binding site for p53. Nat Genet 1: 45-49
8. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, and Levine J (1988) Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 8: 531-539
9. Finlay CA, Hinds PW, Levine AJ (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57: 1083-1093
10. Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR (1994) Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer 69: 26-31
11. Funk WD, Pak DT, Karas RH, Wright WE, Shay JW (1992) A transcriptionally active DNA-binding site for human p53. Mol Cell Biol 12: 2866-2871
12. Halevy O, Michalovitz D, Oren M (1990) Different tumor-derived p53 mutants exhibit distinct biological activities. Science 250: 113-116
13. Hall PA, McKee PH, Menage HduP, Dover R, Lane DP (1993) High levels of p53 protein in UV-irradiated normal human skin. Oncogene 8: 203-207
14. Harris CC, Hollstein M (1993) Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 329: 1318-1327
15. Hartmann LC, Podratz KC, Keeney GL, Kamel NA, Edmonson JH, Grill JP, Su JQ, Katzmann JA, Roche PC (1994) Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 12: 64-69
16. Hinds PW, Weinberg RA (1994) Tumor suppressor genes. Curr Opinion Genet Dev 4: 135-141
17. Hinds P, Finlay C, Levine A (1989) Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63: 739-746
18. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 Mutations in human cancers. Science 253: 49-53
19. Kastan MB, Onyinye O, Sidransky D, Vogelstein B, Craig R (1991) Participation of p53 in the cellular response to DNA damage. Cancer Res 51: 6304-6311
20. Kihana T, Tsuda H, Teshima S, Okada S, Matsuura S, Hirohashi S (1992) High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 83: 978-984
21. Kohler MF, Kerns BJM, Humphrey PA, Marks JR, Bast RC, Berchuck A (1993) Mutation and overexpression of p53 in early stage ovarian cancer. Obstet Gynecol 5: 643-650
22. Kraiss S, Spiess S, Reihsaus E, Montenarh M (1991) Correlation of metabolic stability and altered quaternary structure of oncoprotein p53 with cell transformation. Exp Cell Res 192: 157-164
23. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89: 7491-7495
24. Kupryjanczyk J, Thor AD, Beauchamp R, Merrit V, Edgerton SM, Bell DA, Yandell DW (1993) p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 90: 4961-4965
25. Kupryjanczyk J, Bell DA, Yandell DW, Scully RE, Thor AD (1994) p53 expression in ovarian borderline tumors and stage I carcinomas. Am J Clin Pathol 102: 671-676
26. Lee ET (1980) Statistical methods for survival data analysis. Lifetime Learning, Belmont, Calif
27. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453-456
28. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL (1991) Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51: 2979-2984
29. Mazars R, Pujol P, Maudelonde T, Jeanteur P, Theillet C (1991) p53 mutations in ovarian cancer: a late event? Oncogene 6: 1685-1690
30. Miller C, Mohanadas T, Wolf D, Prokocimer M, Rotter V, Koeffler HP (1986) Human p53 gene localized to short arm of chromosome 17. Nature 319: 783-784
31. Milner BJ, Allan LA, Eccles DM, Kitchener HC, Leonard RCF, Kelly KF, Parkin DE, Haites NE (1993) p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 53: 2128-2132
32. Naito M, Satake M, Sakai E, Hirano Y, Tsuchida N, Kanzaki H, Ito Y, Mori T (1992) Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis. Jpn J Cancer Res 83: 1030-1036
33. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature 342: 705-708
34. Rasbridge SA, Gillett CE, Seymour A-M, Millis RR (1993) The effect of chemotherapy on histological and biological features of breast carcinoma. J Pathol 169 |Suppl|: 191
35. Soussi T, Caron de Fromentel C, May P (1990) Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5: 945-952
36. Thor AD, Moore DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS (1992) Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J National Cancer Inst 84: 845-855
37. Vogelstein B, Kinzler KW (1992) p53 function and dysfunction. Cell 70: 523-526
38. Vojtesek B, Bártek J, Midgley CA, Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. J Immunol Methods 151: 237-244
39. Younish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimichi A, Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352: 345-347
40. Zambetti GP, Bargonetti J, Walker K, Prives C, Levine AJ (1992) Wild type p53 mediates positive regulation of gene expression through a specific DNA sequence element. Genes Dev 6: 1143-1152